RxDoctor Payments Data

Regina Afriyie

Psychiatric/Mental Health · Largo, MDNPI 1124776224

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,902in general payments, 2019–2025

Across 233 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$876
  • Otsuka America Pharmaceutical, Inc.$691
  • Teva Pharmaceuticals USA, Inc.$667
  • Vanda Pharmaceuticals Inc.$532
  • Johnson & Johnson$504
  • Lundbeck LLC$443
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,76897%
  • Education$1343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,902 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$119,786
Abilify MaintenaAripiprazole20$54,648
Aripiprazole24$2,739
Clozapine21$1,127
Fluoxetine Hcl28$837
Divalproex Sodium31$547
Trazodone Hcl92$538
Olanzapine22$512
Haloperidol22$469
Amitriptyline Hcl28$393
Quetiapine Fumarate48$369
Clonazepam62$337
Hydroxyzine Hcl22$293
Benztropine Mesylate56$267
Perphenazine11$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$161$119,78614 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$691$54,64820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Largo

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →